MELVIN R. MOORE, M.D.; JOAN M. BULL, M.D.; STEPHEN E. JONES, M.D.; SAUL A. ROSENBERG, M.D., F.A.C.P.; HENRY S. KAPLAN, M.D.
One hundred and two patients with previously untreated Hodgkin's disease, stages IB through IIIB, were randomized within their pathological stage to receive total-lymphoid radiation, either alone or followed by six cycles of MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) therapy. The group receiving radiotherapy alone had 10 relapses, including 2 deaths from disease. The group assigned to sequential radiotherapy and chemotherapy had one relapse. The number of relapses in the group receiving sequential therapy (1/48) was significantly less than that in the group receiving radiotherapy alone (10/45; P < 0.01). The mean duration of follow-up from the end of MOPP chemotherapy in the 35 patients who completed sequential therapy was 375 days. The MOPP therapy was tolerated by patients who had recently received total-lymphoid radiation, and it significantly improved their probability of disease-free survival (P < 0.01). Actual survival was not significantly different for the two groups (P = 0.10).
MOORE MR, BULL JM, JONES SE, ROSENBERG SA, KAPLAN HS. Sequential Radiotherapy and Chemotherapy in the Treatment of Hodgkin's Disease: A Progress Report. Ann Intern Med. ;77:1–9. doi: 10.7326/0003-4819-77-1-1
Download citation file:
Published: Ann Intern Med. 1972;77(1):1-9.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use